IDEXX reports Q4 2025 revenue of USD 1.09 billion, up 14%

Reuters02-02 19:31

IDEXX reports Q4 2025 revenue of USD 1.09 billion, up 14%

IDEXX Laboratories Inc. reported fourth quarter (Q4) 2025 revenues of USD 1.09 billion, reflecting a 14% increase compared to the prior year period. The Companion Animal Group $(CAG)$ segment achieved reported revenue growth of 15%, while Water revenue grew 12% year-over-year. Earnings per diluted share $(EPS)$ for Q4 2025 were USD 3.08, up 18%, with operating margin expansion of 1.5 percentage points. For the full year (FY) 2025, IDEXX Laboratories highlighted continued strong execution, driven by the successful launch of the IDEXX Cancer Dx canine lymphoma test and significant adoption of the IDEXX inVue Dx instrument, both of which exceeded initial adoption targets. The company also noted positive impacts from currency changes and tax benefits related to share-based compensation during the quarter. IDEXX Laboratories Inc. enters 2026 with an expanded innovation pipeline and plans to build on its installed base of premium instruments and further international expansion of its diagnostics solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260130438354) on February 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608863499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608863499","market":"us","top_or_hot":-1,"title":"IDEXX reports Q4 2025 revenue of USD 1.09 billion, up 14%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IDEXX reports Q4 2025 revenue of USD 1.09 billion, up 14%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IDEXX Laboratories Inc. reported fourth quarter (Q4) 2025 revenues of USD 1.09 billion, reflecting a 14% increase compared to the prior year period. The Companion Animal Group <a href=\"https://laohu8.com/S/CAG\">$(CAG)$</a> segment achieved reported revenue growth of 15%, while Water revenue grew 12% year-over-year. Earnings per diluted share <a href=\"https://laohu8.com/S/EPS\">$(EPS)$</a> for Q4 2025 were USD 3.08, up 18%, with operating margin expansion of 1.5 percentage points. For the full year (FY) 2025, IDEXX Laboratories highlighted continued strong execution, driven by the successful launch of the IDEXX Cancer Dx canine lymphoma test and significant adoption of the IDEXX inVue Dx instrument, both of which exceeded initial adoption targets. The company also noted positive impacts from currency changes and tax benefits related to share-based compensation during the quarter. IDEXX Laboratories Inc. enters 2026 with an expanded innovation pipeline and plans to build on its installed base of premium instruments and further international expansion of its diagnostics solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260130438354) on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEXX reports Q4 2025 revenue of USD 1.09 billion, up 14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEXX reports Q4 2025 revenue of USD 1.09 billion, up 14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-02 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IDEXX reports Q4 2025 revenue of USD 1.09 billion, up 14%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IDEXX Laboratories Inc. reported fourth quarter (Q4) 2025 revenues of USD 1.09 billion, reflecting a 14% increase compared to the prior year period. The Companion Animal Group <a href=\"https://laohu8.com/S/CAG\">$(CAG)$</a> segment achieved reported revenue growth of 15%, while Water revenue grew 12% year-over-year. Earnings per diluted share <a href=\"https://laohu8.com/S/EPS\">$(EPS)$</a> for Q4 2025 were USD 3.08, up 18%, with operating margin expansion of 1.5 percentage points. For the full year (FY) 2025, IDEXX Laboratories highlighted continued strong execution, driven by the successful launch of the IDEXX Cancer Dx canine lymphoma test and significant adoption of the IDEXX inVue Dx instrument, both of which exceeded initial adoption targets. The company also noted positive impacts from currency changes and tax benefits related to share-based compensation during the quarter. IDEXX Laboratories Inc. enters 2026 with an expanded innovation pipeline and plans to build on its installed base of premium instruments and further international expansion of its diagnostics solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260130438354) on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0170899867.USD","symbol_name":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL5M9wy4:1","article_id":"2608863499","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608863499","pubTimestamp":1770031885,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IDEXX Laboratories Inc. reported fourth quarter  2025 revenues of USD 1.09 billion, reflecting a 14% increase compared to the prior year period. The Companion Animal Group  segment achieved reported revenue growth of 15%, while Water revenue grew 12% year-over-year. Earnings per diluted share  for Q4 2025 were USD 3.08, up 18%, with operating margin expansion of 1.5 percentage points. For the full year  2025, IDEXX Laboratories highlighted continued strong execution, driven by the successful launch of the IDEXX Cancer Dx canine lymphoma test and significant adoption of the IDEXX inVue Dx instrument, both of which exceeded initial adoption targets. The company also noted positive impacts from currency changes and tax benefits related to share-based compensation during the quarter. IDEXX Laboratories Inc. enters 2026 with an expanded innovation pipeline and plans to build on its installed base of premium instruments and further international expansion of its diagnostics solutions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4567":"ESG概念","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","BK4585":"ETF&股票定投概念","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","BK4082":"医疗保健设备","BK4504":"桥水持仓","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","BK4588":"碎股","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","IDXX":"爱德士实验室","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC"},"translate_title":"IDEXX报告2025年第四季度收入为10.9亿美元，增长14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDXX":0.9},"content_text":"IDEXX reports Q4 2025 revenue of USD 1.09 billion, up 14%\n    \n\n        IDEXX Laboratories Inc. reported fourth quarter (Q4) 2025 revenues of USD 1.09 billion, reflecting a 14% increase compared to the prior year period. The Companion Animal Group $(CAG)$ segment achieved reported revenue growth of 15%, while Water revenue grew 12% year-over-year. Earnings per diluted share $(EPS)$ for Q4 2025 were USD 3.08, up 18%, with operating margin expansion of 1.5 percentage points. For the full year (FY) 2025, IDEXX Laboratories highlighted continued strong execution, driven by the successful launch of the IDEXX Cancer Dx canine lymphoma test and significant adoption of the IDEXX inVue Dx instrument, both of which exceeded initial adoption targets. The company also noted positive impacts from currency changes and tax benefits related to share-based compensation during the quarter. IDEXX Laboratories Inc. enters 2026 with an expanded innovation pipeline and plans to build on its installed base of premium instruments and further international expansion of its diagnostics solutions.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260130438354) on February 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608863499","isCrawlerRequest":true}